Avantika Gupta
@AvanGupta
Postdoc @MSKCancerCenter studying mutagenesis and resistance mechanisms
So excited to share our latest work with Sarat Chandarlapaty, @antoniomarraMD, Andrea Gazzo @MSKCancerCenter out today in @NatureGenet! We uncover the function and mechanism of APOBEC3-driven therapy resistance in breast cancer. 🧵 1/ nature.com/articles/s4158…
Honored to present our work on mechanism of mtTP53 in escaping CDK4/6i-induced geroconversion linked to the lack of long-term disease control. Grateful to @NeilVasan for highlighting our research in the Basic Science Year in Review! #SABCS24
A new study in @NatureGenet from MSK's Dr. Sarat Chandarlapaty and colleagues investigates how APOBEC3 #mutagenesis drives therapy resistance in #BreastCancer. Learn more: go.nature.com/45kkqfg
Thank you for your support! Excited to share the story with everyone soon!
Once again excellent work by @AvanGupta showing that #APOBEC3 drives resistance causing mutations. #AACR25 10.1101/2024.04.29.591453 now in press @NatureGenet
Sarat Chandarlapaty expertly summarizing our work on how underlying genomic instability in breast cancer leads to therapy resistance! Come see me expand on the role of APOBEC3 mutagenesis in these processes tomorrow morning at #AACR25!

🎥@AvanGupta of @MSKCancerCenter discusses APOBEC3 signatures as biomarkers of poor outcomes in metastatic breast cancer. Targeting APOBEC-PIK3CA mutations may boost PI3K-alpha inhibitor sensitivity: ➡️ow.ly/TKE850UAkYO⬅️ @SABCSSanAntonio #SABCS24 #BCSM #breastcancer
🎥@AvanGupta of @MSKCancerCenter discusses resistance to trastuzumab deruxtecan (T-DXd) in HER2-low breast cancer. EGFR overexpression limits uptake, but adding cetuximab restores efficacy: ➡️ow.ly/Lt8Q50UAkJS⬅️ @SABCSSanAntonio #SABCS24 #BreastCancer #BCSM #ImmunoOnc
How does a tumor acquire all those resistance promoting alterations in the first place? Kudos to @AvanGupta @MSKCancerCenter for defining the role of #APOBEC3 mutagenesis in this process. #SABCS24